Caisse DE Depot ET Placement DU Quebec Makes New $12.60 Million Investment in Hologic, Inc. (NASDAQ:HOLX)

Caisse DE Depot ET Placement DU Quebec purchased a new stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 174,759 shares of the medical equipment provider's stock, valued at approximately $12,598,000. Caisse DE Depot ET Placement DU Quebec owned 0.08% of Hologic as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in HOLX. Venturi Wealth Management LLC lifted its position in shares of Hologic by 156.3% in the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock worth $31,000 after purchasing an additional 261 shares in the last quarter. EverSource Wealth Advisors LLC lifted its position in Hologic by 79.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock worth $42,000 after buying an additional 260 shares in the last quarter. Smartleaf Asset Management LLC boosted its stake in shares of Hologic by 36.9% during the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock worth $43,000 after buying an additional 159 shares during the last quarter. Smithfield Trust Co grew its holdings in shares of Hologic by 160.0% in the 4th quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider's stock valued at $45,000 after acquiring an additional 400 shares in the last quarter. Finally, Sound Income Strategies LLC acquired a new stake in shares of Hologic in the fourth quarter valued at about $60,000. Institutional investors own 94.73% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have weighed in on HOLX. Needham & Company LLC restated a "hold" rating on shares of Hologic in a research note on Friday, May 2nd. William Blair reiterated an "outperform" rating on shares of Hologic in a research note on Thursday, February 6th. Citigroup lowered their price objective on shares of Hologic from $80.00 to $70.00 and set a "neutral" rating on the stock in a research note on Tuesday, March 4th. StockNews.com downgraded shares of Hologic from a "buy" rating to a "hold" rating in a research note on Monday. Finally, Royal Bank of Canada dropped their price objective on Hologic from $75.00 to $70.00 and set a "sector perform" rating on the stock in a research note on Friday, May 2nd. Twelve analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $79.85.

Hologic Stock Up 0.0 %

Shares of HOLX stock traded up $0.01 on Friday, reaching $56.19. 1,418,697 shares of the company were exchanged, compared to its average volume of 2,913,613. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. The company has a 50-day moving average of $59.55 and a 200-day moving average of $68.52. The company has a market cap of $12.61 billion, a price-to-earnings ratio of 17.73, a PEG ratio of 2.14 and a beta of 0.54. Hologic, Inc. has a one year low of $51.90 and a one year high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.01. The business had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. Hologic had a net margin of 18.42% and a return on equity of 19.72%. Hologic's revenue was down 1.2% compared to the same quarter last year. During the same quarter last year, the firm posted $1.03 EPS. Analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.